» Articles » PMID: 22703554

Hypermethylation of the 5' CpG Island of the P14ARF Flanking Exon 1β in Human Colorectal Cancer Displaying a Restricted Pattern of P53 Overexpression Concomitant with Increased MDM2 Expression

Overview
Publisher Biomed Central
Specialty Genetics
Date 2012 Jun 19
PMID 22703554
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: It has been suggested that inactivation of p14ARF, a tumor suppressor central to regulating p53 protein stability through interaction with the MDM2 oncoprotein, abrogates p53 activity in human tumors retaining the wild-type TP53 gene. Differences in expression of tumor suppressor genes are frequently associated with cancer. We previously reported on a pattern of restricted p53 immunohistochemical overexpression significantly associated with microsatellite instability (MSI), low TP53 mutation frequency, and MDM2 overexpression in colorectal cancers (CRCs). In this study, we investigated whether p14ARF alterations could be a mechanism for disabling the p53 pathway in this subgroup of CRCs.

Results: Detailed maps of the alterations in the p14ARF gene were determined in a cohort of 98 CRCs to detect both nucleotide and copy-number changes. Methylation-specific PCR combined with bisulfite sequencing was used to evaluate the prevalence and distribution of p14ARF methylation. p14ARF alterations were then correlated with MSI status, TP53 mutations, and immunohistochemical expression of p53 and MDM2. The frequency of p14ARF mutations was extremely low (1/98; 1%), whereas coexistence of methylated and unmethylated alleles in both tumors and normal colon mucosa was common (91/98; 93%). Only seven of ninety-eight tumors (7%) had a distinct pattern of methylation compared with normal colon mucosa. Evaluation of the prevalence and distribution of p14ARF promoter methylation in a region containing 27 CpG sites in 35 patients showed a range of methylated CpG sites in tumors (0 to 25 (95% CI 1 to 13) versus 0 to 17 (95% CI 0 to 2)) in adjacent colon mucosa (P = 0.004). Hypermethylation of the p14ARF promoter was significantly correlated with the restricted p53 overexpression pattern (P = 0.03), and MDM2 overexpression (P = 0.02), independently of MSI phenotype. Although no significant correlation between p14ARF methylation and TP53 mutational status was seen (P = 0.23), methylation involving the proximal CpG sites within the 5' CpG flanking exon 1β was present more frequently in tumors with restricted p53 overexpression than in those with diffuse p53 overexpression (range of methylated clones 17 to 36% (95% CI 24 to 36%) versus range 0 to 3% (95% CI 0 to 3%), P = 0. 0003).

Conclusion: p14ARF epigenetic silencing may represent an important deregulating mechanism of the p53-MDM2-p14ARF pathway in CRCs exhibiting a restricted p53 overexpression pattern.

Citing Articles

Epigenetic Alterations Upstream and Downstream of p53 Signaling in Colorectal Carcinoma.

Tomicic M, Dawood M, Efferth T Cancers (Basel). 2021; 13(16).

PMID: 34439227 PMC: 8394868. DOI: 10.3390/cancers13164072.


Regulation of Canonical Oncogenic Signaling Pathways in Cancer via DNA Methylation.

Lu J, Wilfred P, Korbie D, Trau M Cancers (Basel). 2020; 12(11).

PMID: 33143142 PMC: 7692324. DOI: 10.3390/cancers12113199.


Loss of Both USP10 and p14ARF Protein Expression Is an Independent Prognostic Biomarker for Poor Prognosis in Patients With Epithelial Ovarian Cancer.

Han G, Chay D, Yi J, Cho H, Chung J, Kim J Cancer Genomics Proteomics. 2019; 16(6):553-562.

PMID: 31659108 PMC: 6885369. DOI: 10.21873/cgp.20157.


Relationships between p14ARF Gene Methylation and Clinicopathological Features of Colorectal Cancer: A Meta-Analysis.

Zhou Z, Zhang H, Lai J, Diao D, Li W, Dang C PLoS One. 2016; 11(3):e0152050.

PMID: 26999279 PMC: 4801177. DOI: 10.1371/journal.pone.0152050.


Biological significance of promoter hypermethylation of p14/ARF gene: relationships to p53 mutational status in Tunisian population with colorectal carcinoma.

Chaar I, Amara S, Elamine O, Khiari M, Ounissi D, Khalfallah T Tumour Biol. 2013; 35(2):1439-49.

PMID: 24065196 PMC: 3932170. DOI: 10.1007/s13277-013-1198-9.


References
1.
Fitzgerald M, Harkin D, Silva-Arrieta S, MacDonald D, Lucchina L, Unsal H . Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci U S A. 1996; 93(16):8541-5. PMC: 38708. DOI: 10.1073/pnas.93.16.8541. View

2.
Li L, Dahiya R . MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002; 18(11):1427-31. DOI: 10.1093/bioinformatics/18.11.1427. View

3.
Frommer M, McDonald L, Millar D, Collis C, Watt F, GRIGG G . A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci U S A. 1992; 89(5):1827-31. PMC: 48546. DOI: 10.1073/pnas.89.5.1827. View

4.
Midgley C, Desterro J, Saville M, Howard S, Sparks A, Hay R . An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene. 2000; 19(19):2312-23. DOI: 10.1038/sj.onc.1203593. View

5.
Robertson K, Jones P . The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol. 1998; 18(11):6457-73. PMC: 109232. DOI: 10.1128/MCB.18.11.6457. View